Author:
Nguyen Hai Viet,de Haas Petra,Nguyen Hoa Binh,Nguyen Nhung Viet,Cobelens Frank G. J.,Mirtskhulava Veriko,Finlay Alyssa,Van Nguyen Hung,Huyen Pham T. T.,Tiemersma Edine W.
Abstract
Abstract
Background
Xpert MTB/Rif, a molecular test to detect tuberculosis (TB), has been proven to have high sensitivity and specificity when compared with liquid culture in clinical settings. However, little is known about its performance in community TB screening.
Methods
In Vietnam, a national TB prevalence survey was conducted in 2017. Survey participants who screened positive by chest X-ray, cough symptoms and/or recent history of tuberculosis were requested to provide at least two sputum samples that were tested for Mycobacterium tuberculosis by Xpert MTB/Rif G4 (Xpert) and BACTEC MGIT960 culture (MGIT).
Results
There were 4,649 eligible participants provided both samples for testing. Among them, 236 (5.1%) participants tested positive for TB by Xpert, 244 (5.3%) tested positive by MGIT and 317 tested positive by at least one test; 163 (51.4%) had discordant test results. Of the positive Xpert, 162 (68.6%) showed a low or very low bacterial load. In multivariate logistic regression comparing discordant with Xpert-MGIT concordant positive results, discordant Xpert-positive results occurred more often among participants who had low sputum bacterial load, male sex, a history of TB treatment, or night sweats. The associated factors were male sex, abnormal chest X-ray and having night sweats when the logistic model was against those with both Xpert and MGIT negative.
Conclusions
We found high rates of discordance in the performance of Xpert and MGIT for community-based TB case finding. In situations where the majority of TB cases are expected to have a low bacterial load, multiple diagnostic tests and/or multiple samples are required to reach sufficient sensitivity.
Publisher
Springer Science and Business Media LLC
Reference34 articles.
1. World Health Organisation. Global tuberculosis report 2021. WHO Press. 2021 [cited 2022 Feb 17]. Available from: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2021.
2. Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO’s new end TB strategy. Lancet. 2015. https://doi.org/10.1016/s0140-6736(15)60570-0.
3. Van Deun A, Rieder HL, Kam KM, et al. Priorities for tuberculosis bacteriology services in low-income countries. p 11-12. International Union against Tuberculosis and Lung Disease. 2007. https://tbrieder.org/publications/books_english/red_book.pdf
4. Burzynski J, Schluger NW. PNEUMONIA | Mycobacterial. Amsterdam: Elsevier B.V.; 2006.
5. Xie YL, Cronin WA, Proschan M, Oatis R, Cohn S, Curry SR, et al. Transmission of Mycobacterium tuberculosis from patients who are nucleic acid amplification test negative. Clin Infect Dis. 2018. https://doi.org/10.1093/cid/ciy365.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献